Exscientia

Pharmaceutical AI company designing and developing precision-engineered medicines

Oxford, United Kingdom Founded 2012 201-500 employees SaaS

About Exscientia

Exscientia developed an artificial intelligence platform for drug discovery and medicine design. The company combined computational chemistry, machine learning, and laboratory automation to help pharmaceutical researchers explore candidate molecules and move promising compounds through early-stage research more efficiently. Its technology included AI-supported molecular design, experimental workflows, and automated chemistry capabilities intended to connect in-silico predictions with real-world laboratory testing. Exscientia worked with pharmaceutical and biotechnology partners on programs spanning oncology, immunology, and other areas of unmet medical need, while developing its own drug candidates. In 2024, Exscientia combined with Recursion Pharmaceuticals and became a wholly owned subsidiary, bringing its chemistry design and automated synthesis capabilities into Recursion's broader AI-enabled drug discovery platform. This profile describes Exscientia's drug-design technology and research heritage within the combined organization, rather than presenting it as a standalone independent company.